Rebound hyperresponsiveness to muscarinic stimulation after chronic therapy with an inhaled muscarinic antagonist

In 9 young subjects with mild asthma, we investigated the possibility that chronic daily administration of an inhaled muscarinic antagonist (ipratropium bromide) might increase the response of muscarinic receptors in airway smooth muscle to agonist stimulation caused by receptor upregulation. Subjec...

Full description

Saved in:
Bibliographic Details
Published inThe American review of respiratory disease Vol. 132; no. 1; p. 12
Main Authors Newcomb, R, Tashkin, D P, Hui, K K, Conolly, M E, Lee, E, Dauphinee, B
Format Journal Article
LanguageEnglish
Published United States 01.07.1985
Subjects
Adult
Asthma - drug therapy
Asthma - physiopathology
Bronchi - physiopathology
Bronchial Provocation Tests
Female
Forced Expiratory Volume
Humans
Ipratropium - therapeutic use
Male
Methacholine Chloride
Methacholine Compounds
Muscle, Smooth - physiopathology
Receptors, Muscarinic - physiology
Vital Capacity
Online AccessGet more information

Cover

More Information
Summary:In 9 young subjects with mild asthma, we investigated the possibility that chronic daily administration of an inhaled muscarinic antagonist (ipratropium bromide) might increase the response of muscarinic receptors in airway smooth muscle to agonist stimulation caused by receptor upregulation. Subjects inhaled 60 micrograms of ipratropium 4 times daily for 3 wk. Methacholine bronchoprovocation (with or without acute pretreatment with ipratropium) was performed before (control period) and during 3 wk of daily ipratropium therapy (medication period). At the end of the medication period, subjects returned at 12, 24, 48, and 72 h after the last dose of ipratropium (withdrawal period) to determine the provocative concentration of methacholine producing a 20% decrease in FEV1 (PC20). During the medication period, there was no significant diminution of the acute bronchodilator response to ipratropium or of the protective effect of ipratropium against methacholine-induced bronchospasm when compared with the control period. During the withdrawal period, mean in PC20 was significantly less (increased airway responsiveness) at 24 h than during the control period (p less than 0.01) and returned to the control period value within 48 to 72 h. We conclude that daily administration of ipratropium to mildly asthmatic subjects for 3 wk does not produce tolerance to either the bronchodilator effect of ipratropium or to its inhibition of methacholine-induced bronchospasm but does induce transient supersensitivity of airway cholinergic receptors to muscarinic stimulation.
ISSN:0003-0805